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Human holobiomes are networks of mutualistic interactions between human cells and
complex communities of bacteria and fungi that colonize the human body. The immune
systemmust tolerate colonization with commensal bacteria and fungi but defend against
invasion by either organism. Molecular ecological surveys of the human prokaryotic
microbiota performed to date have revealed a remarkable degree of bacterial diversity
and functionality. However, there is a dearth of information regarding the eukaryotic
composition of the microbiota. In this review, we describe the ecology and the human
niches of our fungal “fellow travelers” in both health and disease, discriminating between
passengers, colonizers, and pathogens based on the interaction of these fungi with the
human immune system. We conclude by highlighting the need to reconsider the etiology
of many fungal and immune-related diseases in the context of the crosstalk between the
human system and its resident microbial communities.
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Introduction
Humans live in close association with a complex community of
bacteria, viruses, fungi, and archaea [1–3], which inhabit their
bodies. Many groups have surveyed these microbial popula-
tions using the so-called “next generation” or “deep” sequencing
approaches, revealing that the human microbiota differs radically
at various body sites and among individuals [2–4]. The differences
in the humanmicrobiota are influenced by the availability of nutri-
ents, environmental exposure to microorganisms, and other site-
specific features, such as the immunological makeup of a given
location. The origin of differences in the microbiota between indi-
viduals potentially reflects different patterns of colonization early
in life (reviewed in [5]), different dietary regimens [6, 7], and
different environmental exposures, such as antibiotic use [8, 9].
Recently, the application of deep sequencing approaches have gen-
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erated novel hypotheses about the microbial determinants under-
lying human disorders of immune origin (reviewed in [10]). Sev-
eral metabolites of the interaction between diet and host micro-
biota, such as short-chain fatty acids, have been shown to play
a fundamental role in shaping immune responses (reviewed in
[11]). The application of microbial ecology concepts is ultimately
leading to the conclusion that health and disease can be under-
stood only through an understanding of the ways in which the
symbiotic interactions between microbes and human organs har-
monically integrate in the context of the hologenome [12].
Human microbial diversity is not limited to bacteria; micro-
organisms such as fungi also play major roles in the stability of
microbial communities in human health and disease (reviewed in
[13]). Yeasts were detected in human stool samples as far back
as 1917, and by the mid-20th century the presence of yeasts in
the human intestine was proposed to have a saprotrophic role
[14]. The mycobiota has been initially studied in animals, rang-
ing from ruminants to insects, such as wasps [15] and termites.
These studies paved the way for understanding the role of fungal
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communities in humans. The limited data available thus far sug-
gest that fungal communities are stable across time and are unique
to individuals [16, 17]. Even if the available data are fragmentary
because it relies mostly on culture-based methods, recent reports
using next-generation sequencing technologies also suggest that
diverse fungal communities exist in humans [16, 18]. Fungi and
Blastocystis are the dominant (and in many cases the only) eukary-
otes in the gut microbiota of healthy individuals [16, 19]. More
diversity will likely emerge when more individuals from diverse
populations are sampled using next-generation sequencing, allow-
ing detection of rare taxa. The first culture-independent analysis
of the mycobiota populating a mammalian intestine revealed a
previously unidentified diversity and abundance of fungal species
in the murine gastrointestinal tract [17], indicating that fungi
belonging to four major fungal phyla, Ascomycota, Basidiomycota,
Chytridiomycota, and Zygomycota, account for approximately
2–3% of the total community present in a mucus biofilm. Many
culture-dependent studies on various human niches have readily
isolated yeasts, such as Candida spp., from the mouth, fingernail,
toenail, and rectum of healthy hosts [20]. Microbial eukaryotes
have also been suggested as the causative agents of diseases such
as irritable bowel syndrome, inflammatory bowel disease (IBD),
and “leaky gut” syndrome [16, 21, 22]. The primary aim of this
review is to describe the fungal communities present in various
body sites (Table 1) and the interaction of these fungi with the
immune system. Well aware that the number of studies investigat-
ing the mycobiota association with humans is small, we reviewed
the existing literature describing each fungal species considering
its role as commensal, passenger, or colonizer in health and dis-
ease. The information summarized in Table 1 is indeed going to
rapidly evolve with the exponential increase of community level
genome-wide surveys of the microorganisms inhabiting the var-
ious microenvironments of the human body (i.e., gut, skin, oral
mucosa, and urogenital tract) [23], their environmental reservoir
[24], and the human populations living in different geographic
regions [6, 8].
Understanding the prevalence and distribution of microbial
eukaryotes in addition to prokaryotic microorganisms in the
human body may have important consequences for human health.
While current studies of the human mycobiota focus mainly on
pathogens or opportunistic fungi, most resident microbial eukary-
otes do not cause infections, and are instead either beneficial or
commensal. Elucidating community-wide changes in the human
mycobiota, rather than only the presence or absence of specific
taxa, will be crucial to understanding the cause of, and poten-
tial treatment for, several multifaceted polymicrobial diseases
[25].
Immune response to fungi: Balance between
tolerance and pathogenicity
Immune responses to fungi require PRRs, such as TLRs, C-type
lectin receptors, and the galectin family of proteins [26–28] to
trigger intracellular signaling cascades that initiate and direct
innate and adaptive immune responses [29]. By sensing conserved
molecular structures on fungi, namely the PAMPs, PRRs promote
the activation of the immune system and the clearance of fungi,
with specific immune responses generated depending on the cell
type involved. In a recent review [30], we highlighted the roles
and mechanisms of dectin-1, dectin-2, and DC-SIGN in orchestrat-
ing antifungal immunity, exploring how these PRRs help maintain
homeostasis between potential disease-causing organisms and res-
ident microbial populations. Indeed, the immune system does not
remain ignorant of commensal, passenger (transient), or oppor-
tunistic fungi, and sensing these different fungi through PRRs
serve to ensure that both the symbiotic host–microbial relation-
ship and a homeostatic balance between tolerogenic and proin-
flammatory immune responses are maintained. In light of this,
tissue homeostasis and its possible breakdown in fungal infections
and diseases play a fundamental role.
A number of seminal reviews have addressed the importance
of both resistance — the ability to limit microbial burden — and
tolerance — the ability to limit the host damage caused by an
uncontrolled response — as mechanisms of immune responses
to fungi and the reader is directed to these for more in-depth
information about specific immune mechanisms [31–34].
Monocytes, macrophages, neutrophils as well as epithelial
and endothelial cells [35], mostly contribute to the antifun-
gal innate immune response through phagocytosis and direct
pathogen killing. By contrast, uptake of fungi by DCs promotes
the differentiation of na¨ıve T cells into effector Th-cell subtypes
(Fig. 1). A healthy interaction between fungi and the host requires
the interplay of several Ag-specific adaptive immune responses,
the first step being the activation of the innate fungal detection
system through the PRR.
In tissues, inflammatory signals mediated by direct recogni-
tion of fungal cell wall components or other fungal products
by PRRs, recruit additional immune cells and drive adaptive
immune responses. IFN-γ produced by Th1 lymphocytes is fun-
damental for stimulating the antifungal activity of neutrophils.
The central role of endogenous IFN-γ in the resistance against
systemic fungal infection is underscored by the observation that
KO mice deficient in IFN-γ are highly susceptible to disseminated
C. albicans infection [36]. In addition, mice deficient in IL-18,
which plays a crucial role in the induction of IFN-γ, are also more
susceptible to disseminated candidiasis [37]. Th1 also appears to
be protective in the host defense against Aspergillus. Cells produc-
ing IFN-γ are induced by Aspergillus in immunocompetent mice.
Live conidia, which undergo swelling and germination, are able
to prime Th1 responses [38]. It has been elegantly demonstrated
that CD4+ T cells differentiate during respiratory fungal infec-
tion, with TLR-mediated signals in the lymph node enhancing
the potential for IFN-γ production, whereas other signals pro-
mote Th1 differentiation in the lung [39]. Although many studies
focused on the pathological aspects of IL-17-producing T cells in
many autoimmune diseases, studies examining T-cell polarization
in response to PAMPs have identified an array of fungal compo-
nents that preferentially induce the Th17 lineage [40], suggesting
a role for Th17 cells in fungus-induced host defense, such as those
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Table 1. Different fungal genera dominate different body sites
Fungus Body site Role Presence in health and disease
Aspergillus Skin Opportunistic fungus Presence increased in PID patients [79]
Mouth Opportunistic fungus Present in healthy mycobiota but increased in
immunocompromised patients [82, 111, 112, 114]
Lung Opportunistic
fungus/pathogen
Present in both status but dominant in transplant
patients [122] and CF patients [139, 140] and
known causative agent of ABPA and asthma
Aureobasidium Mouth Commensal/transient Present in health [82]
Blastocystis Gut Commensal Dominant in health [19]
Candida sp.
(in particular
C. albicans)
Skin Commensal Dominant in AD patients [150]
Mouth Commensal/opportunistic
fungus
Present in health [82], dominant in
immunocompromised patients [110, 114]
Lung Commensal/opportunistic
fungus
Present in healthy mycobiota [82], dominant in
transplant patients [122] and in CF [138, 140]
Gut Commensal/opportunistic
fungus
Present in health and disease [19, 151]
Cladosporium sp. Skin Transient during
health/colonizer in disease
Present in AD patients but seldom detected in
healthy samples [104]
Mouth Commensal [82]
Lung Opportunistic fungus Present in transplant patients [122] and contributing
to asthma
Cryptococcus sp.
(in particular
C. diffluens,
C. liquefaciens)
Skin Commensal Dominant in healthy mycobiota [91, 106], decreased
in dandruff-affected individuals [106].
Mouth Commensal Detected as part of healthy mycobiota [82]
Lung Commensal in health,
colonizer, and
opportunistic pathogen
Present in health and disease but dominant in
transplant patients [122]
Debaromyces sp. Skin Commensal Present in health [103]
Filobasidium Skin Opportunistic fungus Increased in dandruff-affected individuals [106]
Fusarium Mouth Commensal [82]
Geotrichum Mouth Opportunistic fungus Detected in immunocompromised patients
[82, 111, 114]
Hemispora Mouth Opportunistic fungus Detected in immunocompromised patients
[82, 111, 114]
Hormodendrum Mouth Opportunistic fungus Detected in immunocompromised patients
[82, 111, 114]
Malassezia sp. Skin Commensal/opportunistic
fungus
Dominant in healthy mycobiota, associated with
several skin diseases such as AD; dominant in
dandruff-affected individuals [116], decreased in
PID patients [79]
Mouth Commensal/opportunistic
fungus
Present in healthy subjects [82]
Lung Opportunistic fungus Increased in CF [138]
Penicillum Mouth Opportunistic fungus Increased in immunocompromised patients
[82, 111, 112]
Lung Opportunistic fungus Present in health but dominant in CF patients [138]
and asthma
Pichia Mouth Commensal/resident Abundant in healthy subjects, decreased during
Candida infection [114]
Pneumocystis Lung Commensal/opportunistic Present at low amount in healthy, causing disease
in immunocompromised hosts [114] and CF
patients [125]
Rhodotorula sp. Skin Commensal Present in healthy subjects [103]
Saccharomycetales
S. cerevisiae
Mouth Commensal/transient Present in health mycobiota [82], dominant in
immunocompromised patients [110]
Gut Commensal/transient Detected in health mycobiota [19, 80, 149] and
during CD (De Filippo et al., submitted)
Scopulariopsis Mouth Opportunistic fungus Detected in immunocompromised patients
[72, 111, 112]
Toxicocladosporium
irritans
Skin Opportunistic fungus Detected in AD patients [104]
The presence in health and disease of the main fungal genera, inhabiting or transiently in contact with the human body, is indicated.
AD: atopic dermatitis; PID: primary immunodeficiency; ABPA: allergic bronchopulmonary aspergillosis.
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Figure 1. Immunological players in the crosstalk betweenmucosal immunity and residentmycobiota. Themajor cells participating in the immune
responses in various body sites are depicted along the human body. (A) The lung and colon mucosa after infection of mice with A. fumigatus and
C. albicans, respectively. Paraffin-embedded tissue sections (3–4 μm) were stained with periodic acid-Schiff reagent and monocytes infiltration at
the site of infections highlighted. Photographs were taken with an Olympus BX51 microscope at 10 or 40× (insets). (B) Lung cellular community.
Ciliated cells sweep the mucus, which protects the luminal zone by transporting antimicrobial peptides, out of the lung. When the fungus
breaks the airway epithelium, released chemokines recruit circulating neutrophils and macrophages. DCs sample the airway lumen by forming
dendritic extensions between epithelial cells. DCs form tight junctions with epithelial cells through their expression of occludin and claudin
family members. Their activation in turn prime the Th-mediated immune response. When allergens are sensed, DCs activate Th2-cell and B-cell
responses, with IgE production. (C) The mucosal barrier of the gut. Ags contact specialized microfold (M) cells overlying Peyer’s patches, which
then process and present the Ag to the immune system. Here, CX3CR1+ macrophages and CD103+ DCs collaborate in capturing soluble food Ags
promoting oral tolerance by activation of T-cell and B-cell responses. When B lymphocytes are stimulated by antigenic material, the cells develop
into Ab-forming cells that secrete various types of Igs, the most important of which is IgA. (D) Skin cellular community. Epidermis is interspersed
with three important immune cell types, Langerhans cells, γδ T cells (termed DETCs) and CD8+ TRM cells representing the first line of defense in
skin immunity. The dermis contains cells of the immune system including Treg cells, CD4+ T effector memory cells (TEM cells), other γδ T cells,
ILCs, and several populations of DCs. Adaptive T-cell response is controlled by resident Treg cells. Mφ, macrophage; LC, Langherans cell; DETC,
dendritic epidermal T cell.
specific for C. albicans, Pneumocystis carinii, and Criptococcus spp.
The observation that mice deficient in IL-17RA show an increased
susceptibility to disseminated C. albicans infection first demon-
strated the critical involvement of Th17 responses in protective
anti-Candida host defenses [41]. Although this suggests a protec-
tive role for Th17 response in fungal infection, negative effects of
Th17-mediated inflammatory responses to intragastric C. albicans
infection in mice have also been reported [42], as well as higher
susceptibility to Candida and Aspergillus infection in absence of
Toll IL1R8 (TIR8), a negative regulator of Th17 responses [43].
On the other hand, patients with impaired Candida-specific Th17
responses, such as patients with chronic mucocutaneous candidi-
asis, are especially susceptible to mucosal C. albicans infections
[44]. These observations strongly indicate that Th17 responses
are important for human anti-Candida mucosal host defense since
patients with genetic defects in the receptor dectin-1 or in its sig-
naling (a potent activator of Th17) suffer from chronic mucosal
fungal infections [45, 46]. Mucosal Th17-cell subsets and their
associated cytokines, IL-17A, IL-17F, and IL-22, have been shown
to play key roles in discriminating colonization and invasive fungal
disease [47–49].
Apart from its protective role, the Th17 response to fungi can be
reciprocally regulated by the Th1, Th2, and regulatory branches
of adaptive immunity and vice versa [50–52]. Both IL-23 and
IL-17 have been shown to impair the antifungal effector activ-
ities of mice neutrophils by counteracting the IFN-γ-dependent
activation of IDO (see below), which is known to limit the inflam-
matory status of neutrophils against fungi, such as A. fumigatus
[53], and which likely accounts for the high inflammatory pathol-
ogy and tissue destruction associated with Th17-cell activation. In
its ability to inhibit Th1 activation, the Th17-dependent pathway
could be responsible for the failure to resolve an infection in the
face of ongoing inflammation. IL-17 neutralization was shown to
increase A. fumigatus clearance, ameliorate inflammatory pathol-
ogy murine lungs, and restore protective Th1 antifungal resistance
[54].
The complex fungal communities encompassing food-borne
and environmental fungi present in the host dictate the
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generation of the different Th-cell subtypes as a result of expo-
sure to different microbial adjuvants. For example, fungal β-glucan
mediated dectin-1 activation on the surface of human DCs induces
CD4+ Th1- and Th17-cell proliferation [55] and primes cytotoxic
T cells in vivo [56]. Other fungal cell wall Ags, such as chitin,
have been shown to alternatively activate macrophages to drive
Th2 immunity [57].
However PRRs might be used by fungi to escape and subvert
the host immune responses in order to survive and eventually
replicate, that is, the C. albicans induction of IL-10 release through
TLR2 [58]. The ability to switch between yeast and hyphal growth
is one of the key virulence attributes of C. albicans: this causes
the blockade of TLR recognition by Ag modification during the
germination of yeasts into hyphae [59]. It is clear that yeast and
hyphae induce different responses [60] by exposing different cell
wall Ags [61] to protective immunity.
Thus, the nature of cell wall Ags likely also serves to promote
a specific inflammatory phenotype. Indeed, fungal pathogenicity
should be examined in the context of features of host responses
to environmental and commensal fungi and the circumstances
that influence the balance between healthy, tolerated exposure to
fungi, and pathogenicity, seen as a loss of balance of the resident
microbial communities and their relative abundance in different
bodily sites and organs.
Fungi as immunoregulators
Commensal microbes significantly shape mammalian immunity,
both at the host mucosal surface and systemically [62, 63], con-
trolling unexpected microbial burden and growth. However, it is
unclear how opportunistic fungi, such as C. albicans, remain at
mucosal surfaces in the face of adaptive immunity as commensals,
that is, as components of themycobiota of a healthy host. Here, the
fungus is controlled by (i) the microbial flora of the healthy host,
(ii) the epithelium, which is able to secrete antimicrobial peptides,
and (iii) the local innate immune system. Candida spp. can clearly
grow in the intestines, coexist with the bacterial microbiota, bloom
during antibiotic perturbations of the microbiota, and colonize
inflamed mucosa, leading to life-threatening infections. Although
the commensal stage is frequently described as “harmless” to the
host, it is likely that this stage is highly regulated and the fungus is
continuously or transiently interacting with the host immune sys-
tem [64]. It is also likely that the human host has evolved to recog-
nize and deal with a potential fungal invader so that the evolved
state is one of commensalism. Treg cells seem to act in tuning
this equilibrium by preventing inappropriate immune responses
that can be damaging to host tissues. Bacher et al. [65] found
that Treg cells specific for A. fumigatus and C. albicans — both
of which inhabit or are in contact with our mucosae — exceeded
in number and functionally suppressed specific memory T cells.
In patients with severe allergic reactions, the Ag-specific memory
T-cell response dominated the immune environment [65]. Thus,
expansion of fungus-specific Treg-cell populations is important for
preventing pathological immune responses.
Indeed, while early inflammation prevents or limits infection,
an uncontrolled response may eventually oppose disease erad-
ication. Counteracting exaggerated effector immune responses
and dysregulated inflammation requires a specific environment in
which not only Treg cells but also tolerogenic DCs play an essential
role. The shift between the inflammatory and anti-inflammatory
states of DCs is strictly controlled by the kynurenine pathway of
tryptophan catabolism, and it has been shown to involve IDO [66].
IDO activates the aryl hydrocarbon receptor (AhR) in lymphoid
tissues [67] and promotes Treg-cell development [68]. In the gas-
trointestinal (GI) tract, diet-derived AhR ligands promote local
IL-22 production by innate lymphoid type 3 cells (ILC3s) [69]. In
combination with IL-17A, IL-22 mediates a pivotal innate antifun-
gal resistance in mice [70] and humans [71]. Zelante et al. [72]
showed that the intestinal microbiota regulates these cytokines,
and in particular a subset of commensal Lactobacilli — L. reuteri
in the stomach and L. acidophilus in the vaginal tract — produce
the metabolite indole-3-aldeyde by tryptophan metabolism, and
indole-3-aldeyde activates AhR in ILCs. This Ahr activation results
in an induced IL-22-mediated antimicrobial response, which in
turn reduces colonization by opportunistic fungi, such as Candida,
providing mucosal protection from inflammation.
In the complex host–pathogen interaction used by both parties
to evaluate the environmental milieu in the ongoing battle for sur-
vival, Candida in turn has been shown to produce immunomodula-
tory compounds, such as oxylipins from the conversion of polyun-
saturated fatty acids [73]. Those molecules interfere with the
metabolism, perception, and signaling processes of cell immune
response.
In parallel, mucosal fungi modulate both the innate and adap-
tive immune responses. In immunocompetent mice, it was shown
that while two consecutive airway exposures to A. fumigatus coni-
dia stimulate neutrophil and macrophage recruitment to the lung
and prime a Th1 response to the fungus, repeated exposures to
A. fumigatus conidia does not result in invasive aspergillosis or
fatal disease, but does result in the development of chronic pul-
monary inflammation [74] mediated by Th2 and Th17 responses.
Therefore, it is likely that repeated pulmonary exposure to A. fumi-
gatus conidia eventually leads to immune homeostasis and the
induction of non-T-cell regulatory pathways that result in the least
possible tissue damage while still controlling conidial germination
[75, 76].
Candida albicans has been shown to have the capacity to “train”
innate immunity toward other microorganisms, such as intestinal
and skin bacteria [77–79]. Furthermore, Saccharomyces cerevisiae,
previously considered a transient microorganism in the intestinal
tract, has been increasingly reported to be present in the human
skin as well [17, 80–82].We recently observed that the presence of
S. cerevisiae among the gut microbiota “educates” the host immune
response by means of training the immune system to better cope
with a secondary infection (Rizzetto et al., unpublished and De
Filippo et al., unpublished).
The immunomodulatory role of commensal organisms has
been formalized by the “hygiene hypothesis,” which suggests that
reduced early exposure to microorganisms is the main cause of the
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early onset of autoimmune or chronic inflammatory disorders in
the industrialized world [83]. Several microorganisms, including
some Clostridium spp., have been shown to drive immunoregula-
tion and to block or treat allergic and autoimmune disease and IBD
[84–86]. The immunoregulatory mechanisms used by several bac-
teria, such as Bacteroides fragilis, Clostridium [84], or by helminths
[85] are based on the specific induction of Treg cells in the colon
or skin, or by the induction of regulatory DCs [87]. We speculate
that an overall reduction in early exposure of humans to beneficial
microbiota is not simply causing a reduction in anti-inflammatory
signals but is more importantly decreasing the “training” of our
immune system to handle pathogenic microorganisms, possibly
resulting in uncontrolled immune responses. Collectively, these
findings show that eukaryotic and prokaryotic communities are
kept in equilibrium by mutual interactions that include the pro-
duction of immune modulating molecules, helping to accommo-
date fungi, either commensals or ubiquitous, within the immune
homeostasis and its dysregulation.
Fungi inhabiting the cutaneous mucosal surface: The
skin mycobiota
The skin represents the primary interface between the human host
and the environment. Cutaneous inflammatory disorders such as
psoriasis, atopic dermatitis (AD), and rosacea have been associ-
ated with dysbiosis in the cutaneous microbiota [88, 89]. Recent
metagenomic studies, investigating the bacterial and fungal com-
ponents of the human skin microbiota of healthy subjects, have
uncovered surprising differences in microbial diversity between
distinct topographical skin sites [81] (Table 1). For example, 11
body sites, including the arm, were found to be dominated by
Malassezia fungi (Table 1), but in contrast, other sites including
the foot (plantar heel, toenail, and toe web) exhibited a broad fun-
gal diversity, with the presence of a wide range of fungal genera
(i.e., Rhodotorula, Debaromyces, Cryptococcus, and Candida) [90].
These results demonstrate that physiologic attributes and topogra-
phy of the skin differentially shape the mycobiota and microbiota
composition.
Indeed a healthy microbiota benefits many aspects of skin
physiology, including wound healing [91], protection against
pathogens [92], and normal development of immune responses
in the skin [77]. Members of the microbiota that dwell deep
in the dermis layers and hair follicles help in recolonization of
the epidermis, hair follicles, and sebaceous glands, and produce
molecules that exert immunoregulatory effects [93]. For instance,
after wounding, staphylococcal lipoteichoic acid has been shown
to inhibit both inflammatory cytokine release and inflamma-
tion triggered by injury through a TLR2-dependent mechanism
[92]. In this complex homeostasis, keratinocytes, which express
many PRRs, such as the TLR family [94], have a key role
in the innate immune response against pathogens, contribut-
ing to both detection and defense [95]. In direct response to
microbes, or through indirect activation by cytokines such as IL-22,
keratinocytes can produce a wide array of antimicrobial peptides,
such as beta-defensin and the cathelicidin LL-37 [96, 97]. Several
other immunological players with various roles in skin immunity
have been detected in the epidermis and dermis (Fig. 1) (for a
review see [98]), such as migratory CD8+ DCs [99]. Langerhans
cells (LCs) contribute to priming adaptive T-cell immunity to skin
pathogens such as yeast (C. albicans) and bacteria (Staphylococcus
aureus), favoring the induction of Th17-cell responses by direct Ag
presentation to Th17 cells [100]. LCs also appear to be immuno-
suppressive, either through inducing T-cell deletion or activating
Treg cells that dampen skin responses to fungi [101]. Using a BM
chimeric mouse model in which only LCs express MHC class II
IE, it was demonstrated that CD4+ T cells responding to Ag pre-
sentation by activated LCs initially proliferated but then failed to
differentiate into effector/memory cells or to survive long term
[101]. The tolerogenic function of LCs was maintained after expo-
sure to potent adjuvants consistently with their failure to translo-
cate the NF-κB family member RelB from the cytoplasm to the
nucleus [101]. This commitment of LCs to tolerogenic function
may explain why commensal microorganisms confined to the skin
epithelium are tolerated, whereas invading pathogens that breach
the epithelium and activate dermal DCs stimulate a strong immune
response.
In the presence of C. albicans, LCs have been shown to stim-
ulate both skin-resident Treg-cell and effector T-cell proliferation
[102]. This specific induction has been demonstrated to be medi-
ated by Ag presentation mechanism — via CD80/86, HLA-DR —
and IL-15 pathways [102]. Together, the above findings support a
model in which LCs provide important regulatory feedback to the
immune system, but also selectively contribute to effector T-cell
responses. Resident commensal organisms on the skin are nec-
essary for optimal cutaneous immunity, through the increase of
IL-1β signaling and amplifying responses in accordance with the
local inflammatory environment [85]. Screening mice deficient in
factors known to drive IL-17A production, Hanski et al. showed
that IL-1R1, and its downstream signaling complex MyD88, play
a dominant role in controlling the production of IL-17A, but not
IFN-γ, by cutaneous T cells. IL-1α production by cutaneous cells
was significantly reduced in germ-free mice and monoassociation
with S. epidermidis restored the production of this cytokine, show-
ing that resident bacteria are necessary to drive effector T-cell
function in the skin [85]. The skin can be a point of entry for
fungal infections when the epithelial barrier is breached, or it can
be a site for disseminated, systemic fungal diseases. For example,
the dryness associated with AD compromises the barrier function
of the skin and as a result AD is associated with high susceptibility
to viral, bacterial, and fungal skin infections [103]. To determine
whether the skin microbiota of patients with AD is different from
that of healthy individuals, Zhang and co-workers used an rRNA
gene clone library of 3647 clones to identify 58 fungal species and
seven unknown phylotypes from AD patients and healthy individ-
uals [104]. As expected, Malassezia species were predominant in
AD patient skin, accounting for 63–86% of the clones identified
from each subject. Overall, the non-Malassezia yeast microbiota of
the patients was more diverse than that of the healthy subjects.
Candida albicans, C. diffluens, and C. liquefaciens as well as the
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filamentous fungi Cladosporiumngi spp. and Toxicocladosporium
irritans were detected in AD samples but were seldom detected in
healthy samples [104]. Although Malassezia yeasts are a part of
the mycobiota of healthy skin, they have also been associated
with a number of diseases affecting the human skin, such as
pityriasis versicolor, folliculitis, seborrhoeic dermatitis and dan-
druff, psoriasis, and AD (for a review see [105]). Changes in
the fungal microbiota of the scalp that accompany dandruff have
been examined [106]. While fungi of the Ascomycota dominated
in both healthy individuals and dandruff patients, fungi of the
Basidiomycota phyla (which includeMalassezia) were significantly
increased in dandruff-afflicted scalps [106]. Specific genera that
were increased in patients with severe dandruff included Filoba-
sidium, which jumped to 94% of the total basiomycetes — com-
pletely replacing the Cryptococcus spp. presents in healthy subjects,
and Malassezia (5%) — which represents a twofold increase over
healthy samples. In addition to the basiomycete fungi of the genus
Cryptococcus, healthy scalps were dominated by Acremonium spp.
and Didymella bryoniae (over 95% of the Ascomycota) [106].
An exemplary recent publication [79] has added further funda-
mental understanding of the role of skin microbiota in activating
and educating host immunity, shedding new light on the inter-
play between the immune system and microbiota. The authors
studied patients with hyper IgE syndrome, a primary immun-
odeficiency resulting from STAT3 deficiency, and compared the
bacterial and fungal skin microbiota at four clinically relevant
sites representing the major skin microenvironments (the nares,
retroauricular crease, antecubital fossa, and volar forearm) [79].
The patients displayed increased ecological permissiveness, char-
acterized by altered microbial population structures including col-
onization with bacterial microbial species not observed in healthy
individuals, such as Clostridium species and Serratia marcescens
[79]. An elevated fungal diversity and increased representation
of opportunistic fungi (Candida and Aspergillus) were observed in
hyper IgE syndrome patients, concomitant with a decrease in the
relative abundance of the common skin fungus Malassezia [79].
These changes supported the hypothesis of increased skin permis-
siveness to microbial transit, suggesting that skin may serve as
a reservoir for the recurrent fungal infections observed in these
patients [79].
The differences in the cutaneous microbiota between healthy
individuals and primary immunodeficiency patients probably
correlate with their immunological status. Defects in STAT3
signaling impair defensin expression and the generation and
recruitment of neutrophils [107], in part due to defects in Th17-
cell differentiation. These findings further suggest that altered
immune responses in disease modify not only the bacterial micro-
biota niche but also the fungal skin/mucosal communities, which
may contribute to the increased fungal infections observed clini-
cally in this patient population. The skin microbiota investigation
provides an important step toward understanding the interac-
tions between pathogenic and commensal fungal and bacterial
communities, and how these interactions can result in benefi-
cial or detrimental (i.e., disease) outcomes. Species often con-
sidered “normal” colonizers of the skin, such as Malassezia, can
become causal agents of skin diseases. These preliminary results
indicate the difficulty of defining a “normal” microbiota and con-
sequently, meaningfully linking the mycobiota with clinical status
would require a significant increase in the number of samples
analyzed.
Fungi inhabiting the mouth: The oral mycobiota
The oral microbiota is a critical component of health and dis-
ease. Disruption of this community has been proposed to trigger
or influence the course of oral diseases such as periodontal dis-
ease and oral mucositis, especially among immunocompromised
patients such as those undergoing chemotherapy and HIV patients
(reviewed in [108]). Metagenomic sampling of individual sites
within the oral cavity shows that there are probably hundreds
of different microbial niches in the human mouth [58, 59]. The
fungal component of the oral microbiota, however, has been only
recently characterized.
Ghannoum et al. performed the most comprehensive study
to date on the fungal microbiota of the mouth by using a mul-
titag pyrosequencing approach, combined with the use of pan-
fungal internal transcribed spacer (ITS) primers [82]. The authors
found that the distribution of fungal species in the mouth var-
ied greatly between different individuals. The mycobiota of a
healthy human mouth encompasses 74 cultivable and 11 non-
cultivable fungal genera [82]. The core fungal mycobiota com-
prises Candida species (the most frequent, isolated from 75% of
participants), Cladosporium (65%), Aureobasidium (50%), Sac-
charomycetales (50%), Aspergillus (35%), Fusarium (30%), and
Cryptococcus (20%) [82]. Four of these main genera, namely
Aspergillus, Fusarium, Cryptococcus, and Cladosporium, are known
human pathogens: the impact of their presence as a warning signal
of increased risk of infection needs to be addressed. The remain-
ing 60 nonpathogenic fungi detected in the oral wash samples
represent species that likely originate from the environment in the
form of spores inhaled from the air, or frommaterial ingested with
food. Thus, the presence of these microbes in the oral cavities of
healthy individuals was not necessarily surprising, but the observa-
tion that transient colonization by environmental fungi may occur
in the oral cavity (and upper airways) has potential implications
for hypersensitivity diseases.
Recently, Dupuy et al. detected Malassezia spp. in the saliva
of healthy subjects using high-throughput sequencing analysis
of ITS1 amplicons [109]. As already described, Malassezia spp.
are dominant, highly adapted commensals/pathogens (i.e., their
pathogenic potential is unleashed upon failure from the immune
system to keep them at bay) of human skin, suggesting a potential
additional importance of these organisms in the core mycobiota
of the healthy human mouth.
The presence of pathogenic fungal isolates in the oral cavity
of healthy individuals is quite unexpected and the clinical rel-
evance is unknown. It is possible that the presence of a given
fungal isolate in an individual could be the first step toward
predisposing that individual to opportunistic infections. The
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pathogenicity of the fungi in the oral environment may be con-
trolled in healthy individuals by other fungi or other member of
the oral community, as well as by the functional immune sys-
tem, suggesting that interdependent crosstalk may exist between
constituents of the oral mycobiota. Surveying 18S rDNA using
a PCR-based approach, Aas et al. [110] reported the presence
of C. albicans and S. cerevisiae in the subgingival plaque micro-
biota of HIV-infected patients. Other fungi previously found in the
oral cavity of immunocompromised patients include Penicillium,
Geotrichum, Aspergillus, Scopulariopsis,Hemispora, andHormoden-
drum [89, 111, 112], although the representation of species seems
to correlate with the geographic area of sampling [113]. Recently,
Mukherjee et al. used pyrosequencing to characterize the oral
microbiota of 12 HIV-infected patients and 12 healthy subjects
[114]. The core oral bacterial microbiota comprised 14 genera,
of which 13 were common between patients and healthy sub-
jects. In contrast, the core oral mycobiota differed more between
HIV-infected and -uninfected individuals, with Candida being
the predominant species in immunocompromised patients (98
versus 58% in healthy subjects). Among HIV-infected patients,
Candida, Epicoccum, and Alternaria were the most common gen-
era, while in uninfected participants, the most abundant fungi
were Candida, Pichia, and Fusarium. Increase in Candida colo-
nization, particularly that of C. albicans, was associated with a
concomitant decrease in the abundance of Pichia—a resident oral
fungus representing the 33% of healthy oral mycobiota, suggest-
ing an antagonistic relationship. Indeed, Pichia has been shown to
inhibit growth of pathogenic fungi such as Aspergillus and Candida
by inhibiting the ability of these genera to adhere, germinate, and
form biofilms in vitro [114].
Oral Candida colonization is a known risk factor for invasive
Candidiasis [115]. Similarly, fungal caused periodontal disease
is associated with rheumatoid arthritis [116] and atherosclerosis
[117], suggesting that bacterial and fungal microbiota from the
oral cavity may contribute to the development of certain human
diseases.
Fungi inhabiting the respiratory tract: The lung
mycobiota
The human respiratory tract represents the major entry point for
numerous microorganisms, primarily airborne viruses, bacteria,
and fungal spores. Certain characteristics of these microorgan-
isms, such as Aspergillus spp., coupled with the local host immune
response, determine whether the microorganisms will be cleared
by the immune system or adhere to and colonize the airways,
leading to acute or chronic pulmonary disease [118].
The lower respiratory tract (trachea, bronchi, and pulmonary
tissue), previously thought to be sterile when healthy, has recently
been shown to clearly harbor a low level bacterial microbiota,
which changes during disease (reviewed in [119]). Any microbe,
be it a bacterium or a fungus, reaching the lower respiratory tract
encounters the efficient cleansing action of the ciliated epithelium.
Microorganisms are also subsequently removed by coughing,
sneezing, and swallowing. However, if the respiratory tract
epithelium becomes damaged, as in the case of bronchitis or viral
pneumonia, the individual may become susceptible to infection by
pathogens descending from the nasopharynx (upper respiratory
tract). The bacterial component of the microbiota of a healthy
host has been addressed more deeply than its fungal counter-
part. The bacterial microbiota consists of nine core genera:
Prevotella, Sphingomonas, Pseudomonas, Acinetobacter,
Fusobacterium, Megasphaera, Veillonella, Staphylococcus, and
Streptococcus [120, 121] but little data exist about the fungal
microbiota of the lungs, with the exception of Pneumocystis spp.
In a recent study by Charlson et al., the fungal microbiota of the
mouth and lungs in select healthy and lung transplant recipients
was analyzed by ITS-based pyrosequencing [122]. The fungal
distribution in the oral wash of healthy subjects was similar to
that found in the study by Ghannoum et al. [82]. In the lung
transplant recipients, the fungal microbiota of the oral cavity
was dominated by Candida, likely depending on the antibiotic
and immunosuppressant used by these patients [122]. The
bronchoalveolar lavage from lung transplant recipients showed
detectable Candida spp., Aspergillus spp., or Cryptococcus spp.
Because all of the transplant recipients had been treated with
antibiotics and immunosuppressants, thus ablating host immune
responses and the prokaryotic milieu of the lung microbiota, this
first study supports the notion that host defense, and perhaps
some sort of bacterial microbiota-mediated resistance mecha-
nisms, play a major role in keeping fungal colonization extremely
low in the lungs.
Numerous studies have indicated that Th17 cells and their
signature cytokine IL-17A are critical to the airway’s immune
response against various infections, including intracellular bac-
teria [123, 124] and fungi [125]. The innate IL-17A-producing
cells, γδ T cells have been shown to act on nonimmune lung
cells in infected tissues to strengthen innate immunity by induc-
ing the expression of antimicrobial proteins and inflammatory
chemokines as CCL28, in those cells, causing the migration of
IgE-secreting B cells to the infected tissues [126] as well as the
proliferation of human airway epithelial cells in vitro. Addition-
ally, IL-17A production by pulmonary γδ T cells in the early phase
of tuberculosis infection stimulates neutrophil recruitment to the
infected tissues [127, 128].
Neutrophils release their genomic DNA into the extracellular
environment in the form of neutrophil extracellular traps (NETs)
[129] and ensnare invading pathogens [130, 131]. NETs were
found to be induced by opportunistic fungi such as C. albicans
[130] in a human in vitro study that demonstrated that NETs
interact with yeast in both the single-cell form as well as the
multicellular hyphal form, and incapacitate both forms via the
action of the granular components of the NETs [130].
In contrast to the protective immune response exemplified
by Th1 and Th17 cells [132], Th2 effector cells are consid-
ered deleterious in lung fungal infections, in part because they
dampen the protective Th1-cell responses. The detrimental Th2
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responses in pulmonary fungal infections cause significant clin-
ical problems because Th2 responses are closely related to
allergic inflammation and asthma. One example of a detrimental
fungal Th2-cell response in the lung is that generated by allergic
bronchopulmonary aspergillosis, which can result from inhalation
of the fungal spores of Aspergillus spp. [133]. Indeed, the severity
of asthma is associated with the presence of Alternaria, Aspergillus,
Cladosporium, and Penicillium species in the lung, exposure to
which may occur indoors, outdoors, or both [118]. In order to
improve upon current treatments for invasive fungal infections, it
is imperative to understand the nature of fungal pathogenesis not
only in the context of the diversity of fungal strains present in the
lung [134] but also the complex interplay between lung-colonizing
microbial communities and invading pathogens.
As mentioned before, one notable component of the lung
mycobiota of a healthy individual is Pneumocystis spp. [135].
New molecular surveys are revealing that Pneumocystis is car-
ried at low levels, even in healthy individuals. This fungus can
be spread from individual to individual through airborne trans-
mission, but it can also cause pneumonia following overgrowth
in HIV-immunocompromised hosts [136]. Pneumocystis has also
been implicated as a cofactor of chronic obstructive pulmonary
disease [137]. Thus, Pneumocystis appears to exist as a very low
level commensal in the lung microbiota when the host is healthy
and becomes pathogenic when the host becomes immunocompro-
mised.
Cystic fibrosis (CF) provides an important example of the need
to enhance our knowledge of the composition of the microbial
community in order to improve management of patients suscepti-
ble to pulmonary infections. Using pyrosequencing, Delhaes et al.
[138] extensively explored the diversity and dynamics of fungal
and prokaryotic populations in the lower airways of CF patients.
The authors identified 30 genera, including 24micromycetes, such
as Pneumocystis jirovecii or Malassezia sp., and six basidiomyce-
tous fungi [138]. Among the organisms identified, filamentous
fungi belonging to the genera Aspergillus and Penicillium had pre-
viously been suggested as pathogens in CF patients [139]. Candida
albicans and C. parapsilosis were also recently described as colo-
nizer organisms of CF patients [140, 141]. A significant propor-
tion of other identified species were fungi also detected in patients
with asthma (Didymella exitialis, Penicillium camemberti), allergic
responses (A. penicilloides and Eurotium halophilicum) [142, 143],
or infectious diseases (Kluyveromyces lactis, Malassezia sp., Cryp-
tococci non-neoformans, Chalara sp.) [144]. Fungal colonization
(especially repeated or chronic colonization) may thus have a sub-
stantial impact on the development of CF and other pulmonary
diseases, but more studies are required to determine the real risk
relative to the fungal component of the lung microbiota, especially
because the coexistence of the bacterial component must be taken
into account. A modification in lung mycobiota may result from a
primary dysbiosis of bacteria transiently to persistently colonizing
the lung [145, 146]. Indeed, the causative or the correlative rela-
tion between changes in lung mycobiota and disease onset needs
to be proven by expanding the number of samples and moving
forward the study from the species to the strain level.
Fungi inhabiting the GI mucosal surface: The gut
mycobiota
The human GI tract is known to contain a variable fungal micro-
biota, but the phylogenetic characteristics of those fungal microor-
ganisms and their specific roles as part of the GI tract ecosystem
have not yet been studied extensively. Despite its harsh environ-
ment, the stomach harbors a microbiota that can include Lac-
tobacillus, Helicobacter, and Candida spp. [147]. Candida colo-
nization of the GI tract of mice has been shown to drive allergic
sensitization to food Ags by affecting the mucosal barrier [148].
In particular, intragastrically inoculated mice were administered
with OVA to assess Ag sensitization and GI permeability, and anti-
OVA Ab titers and plasma concentrations of OVA were measured
weekly. The authors showed that C. albicans promoted allergic
sensitization was due to mast cell mediated hyperpermeability
in the GI mucosa [148]. In healthy human volunteers, another
group carried out both culture-independent analyses, based on
DNA extraction and PCR targeting of both total eukaryotic 18S
rRNA genes and fungal ITS, together with culture-dependent anal-
yses of fungi [19]. This study found that the eukaryotic diversity
of the human gut is low, largely temporally stable, and dominated
by various subtypes of Blastocystis and Candida [19]. The low
diversity is likely an artifact due to the fact that the most abun-
dant species occur in the cultivable fraction, particularly Candida
spp. The culture-independent analysis revealed a greater number
of genera, such as Gloeotinia/Paecilomyces and Galactomyces, sug-
gesting the importance of using culture-independent surveys to
assess species composition [19]. An example of the large variabil-
ity of the human gut mycobiota was recently provided by a study
of four children and their respective mothers, which reported that
infants harbor Saccharomyces spp. as opposed to Candida as the
most frequent fungal species in the gut (36%) with respect to their
mothers [149].
Whether S. cerevisiae is present in the human gut at birth
remains to be elucidated. It is possible that yeasts simply reach
the GI tract through food. Fermented foods and beverages con-
taining eukaryotic species such as bread, beer, and wine are con-
sumed on a daily basis, providing ready inocula for the host [19].
Alternatively, it is possible that differences in fungal colonization
are related to differences in the genetic makeup of the host or
differences in gut permeability.
The numerous and diverse interactions between fungi, bacte-
ria, and immune responses can significantly impact gut health and
likely contribute to the pathobiology of GI disorders from irritable
bowel syndrome to IBD. When mucosal homeostasis breaks down
in a genetically predisposed individual, the resulting immune
response may lead to chronic inflammation [150]. Antibodies
against S. cerevisiae have been shown to be disease marker for
Crohn’s disease (CD) [151], possibly indicating that fungi could
play a role in the aberrant immune responses in IBD [152]. A few
studies have been conducted to examine fungal community dys-
biosis in chronic disease, including that in IBD [16, 153]. Fungal
diversity in the large intestine of patients with CD is higher than
that seen in healthy subjects [16]. The study of the mycobiome
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in a murine model of induced colitis highlighted the importance
of the gut mycobiota in contributing to the boost in intestinal
inflammation seen upon dextran sodium sulfate (DSS) treatment
[152], with a marked increase in the abundance of C. tropicalis
observed during active colitis. These studies are the first steps
toward clarifying the role of the gut mycobiota in intestinal inflam-
mation, and may help explain the increased serum levels of anti-
S. cerevisiae antibodies in CD patients [151]. A number of other
opportunistic infections are generally ascribed to defective host
immunity but may require specific microbial population dysbiosis
[153]. Longitudinal molecular typing studies indicate that dissem-
inated C. albicans infections originate from an individual’s own
commensal strains [154], and the transition to virulence is gener-
ally thought to reflect impaired host immunity. However, recent
data indicate that the ability of a commensal organism to produce
disease is not merely a consequence of impaired host immunity.
Suzanne Noble and colleagues [155] showed that the opportunis-
tic pathogen C. albicans can enter a specific, regulated commensal
state called GUT (gastrointestinally induced transition) in the host
intestine. Candida albicans in the GUT state have a unique pheno-
type that promotes carriage in the gut in a benign state, in which
virulence-associated genes, such as the white-opaque switching
and hyphal formation genes, are downregulated, enabling fungal
adaptation for long-term survival in the large intestine [155]. Nev-
ertheless, GUT cells can promote pathogenesis when host immu-
nity is impaired. These new findings suggest that more attention
will be directed toward understanding fungal persistence, colo-
nization, and commensalisms — processes that may have evolved
over many thousands of years of coevolution within the human
host.
Diet is a constant and dynamic factor shaping mucosal immu-
nity as well as the composition of resident microbial populations in
the gut. To maintain gut homeostasis, immune cells must sample
Ags from the intestinal lumen and deliver them to lymph nodes
for presentation to T cells (Fig. 1). In the lymph nodes, CX3CR1+
macrophages and CD103+ DCs collaborate in a fascinating way
to capture soluble food Ags [156] and induce oral tolerance. In
addition, ILC3s control the production of cytokines important for
control of fungal burden, such as IL-17 and IL-22 [157]. Hoffmann
et al. investigated the association of diet with fungal populations,
using fecal samples from 98 healthy individuals [158]. They char-
acterized 62 fungal genera and 184 species by deep sequencing,
and usually found that the presence of either the phyla Ascomy-
cota or Basiodiomycota was mutually exclusive. The authors could
not conclude which of those fungi are true gut residents and which
are passengers resulting from diet. We cannot exclude the possi-
bility that the presence of Saccharomyces is due to the ingestion
of yeast-containing foods such as bread and beer [82]. A recent
study conducted on the Wayampi Amerindian community showed
a high diversity among yeast species in the gut, with a prevalence
of S. cerevisiae over Candida species [80], suggesting a role for
this fungus in gut immune homeostasis. Thus, integrating infor-
mation on the repertoire of the gut mycobiota in the context of
the broader microbiota and developing functional tests to measure
its role in shaping immune function is necessary to better under-
stand the role of the microbial communities in sustaining human
health.
Microorganisms and the immune system exhibit
crosstalk between the gut and various organs
Although we have described the composition of the fungal micro-
biota in various locations in the human body, we remain aware
that these locations are not isolated and that DCs trained in the
Peyer’s patches of the intestine (Fig. 1) can shape T-cell responses
in other locations. A clear example of this crosstalk was recently
shown in an elegant study by Kim et al. [159], who showed
that antibiotic treatment of mice increases susceptibility to aller-
gic airway disease by promoting varying degrees of fungal out-
growth in the intestine, ultimately resulting in the acquisition of
anM2 phenotype by alveolar macrophages [159]. The authors iso-
lated C. parapsilosis from the feces of antibiotic-treated mice and
showed that transferring this fungus to mice that did not carry
this species increased their susceptibility to allergic airway inflam-
mation induced by papain or house dust mite extract [159]. Oral
treatment of mice with Candida species isolated from humans also
led to fungal outgrowth in the gut and exacerbated allergic air-
way inflammation, increasing serum levels of prostaglandin E2,
which promoted the development of M2 macrophages [159]. The
mycobiota alteration mediated imbalance in alveolar macrophage
function contributed to the increase in airway inflammation, as
untreated animals receiving alveolar macrophages from antibiotic-
treated mice developed more severe airway inflammation than
animals that received alveolar macrophages from control mice.
Based on this result, it appears that intestinal dysbiosis, particu-
larly the altered ratio of fungi to bacteria, could be a causative
factor in the development of allergic disease. Patients with severe
asthma with fungal sensitization are often sensitized to C. albicans
and benefit from antifungal drug therapy [160]. Colonization of
mice with C. albicans has been shown to result in dietary Ag leak
from the stomach [148]. CD is associated with a microbiotic dys-
biosis and the development of antibodies against members of the
microbiota [161]. This includes anti-S. cerevisiae antibodies, which
have been shown to be reactive to an in vivo expressed epitope
on Candida species, as well as baker’s yeast [149]. Defects in the
C-type lectin, β-glucan receptor dectin-1 — which plays a funda-
mental role in antifungal immunity by β-glucan yeast wall com-
ponent recognition [162] and which deficiency in humans causes
fungal infection susceptibility [50]— confer increased susceptibil-
ity to chemically induced colitis, disease that could be exacerbated
by repeated oral delivery of C. tropicalis [160]. This was consis-
tent with the report that C. albicans could also exacerbate DSS-
induced colitis [163] and that an indigenous Candida population
could drive disease. Similarly, lung responses generated via the
β-glucan receptor dectin-1 are required for lung defense during
acute, invasive A. fumigatus infection through IL-22 production
[164]. Unexpectedly, lung responses generated via dectin-1, in an
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allergic mouse model of chronic lung exposure to live A. fumigatus
conidia, lead to the induction of multiple proallergic (Muc5ac,
Clca3, CCL17, CCL22, and IL-33) and proinflammatory (IL-1β and
CXCL1) mediators that compromised lung function [165]. Assess-
ment of cytokine responses demonstrated that purified lung CD4+
T cells produced IL-4, IL-13, IFN-γ, and IL-17A, but not IL-22, in a
dectin-1-dependent manner [108]. Overall we can conclude that
dectin-1 contributes to both protection and gut and lung inflam-
mation and immunopathology associated with persistent fungal
exposure, via mechanisms that involve constant integration of
messages derived from different locations in the body.
Conclusions
Recent culture-independent surveys of eukaryotic communities
reveal that, similar to bacteria, commensal fungi are an essential
part of human ecosystems. The role of the mycobiota in the main-
tenance of health can be understood only using a “systems level”
integrated ecological approach, as opposed to an approach focused
on specific, disease-causing taxa. Strain-specific traits, such as dif-
ferences in cell wall composition among isolates from the same
fungal species, may prove to be as important as differences in
mycobiota species composition to maintain the correct immune
homeostasis [134, 166]. Previous results demonstrating a switch
from a Th1-Treg response to a Th17 response following exposure
to different life stages of the same strain of S. cerevisiae [167],
as well as the results showing the Candida GUT phenotype shift
[155] are clear examples of the need to functionally analyze the
mycobiota at the strain level, rather than simply counting its parts
at the species level.
This analysis will require sequencing and annotating many
more fungal genomes than are currently known, developing
strains specific markers as well as gaining an understanding of
their population and community structures in the context of the
evolutionary forces shaping their adaptation to the host. High-
throughput analysis of fungal cells walls as well as in-depth
sequencing of the meta-transcriptome of eukaryotes during the
interaction with the host immune system will soon offer a novel
window into the integrated functioning of the mycobiota and
microbiota.
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